Cocrystal Pharma, Inc.
corporate_fare Company Profile
Cocrystal Pharma, Inc. (NASDAQ:COCP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for COCP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for COCP spans 10-Q, 8-K, SCHEDULE 13D/A, DEF 14A.
Recent high-impact activity:
- Cocrystal Q3 Loss Widens to $3.4M; Going Concern Reiterated With $4.9M Cash
- Cocrystal Pharma Completes Dosing in Phase 1b Norovirus Study for CDI-988; No Serious Adverse Events Reported
- Cocrystal Pharma Q2 10-Q: Going Concern Persists Despite $5M OPKO Placement
- Phillip Frost Lifts Cocrystal Stake to 13.9% with $80K in Open-Market Buys
- Cocrystal Pharma Secures $5M Private Placement from OPKO Health, Extending Cash Runway
Financial Snapshot
Short Interest & Short Volume
4.92 days to coverFINRA reported short interest of 181,361 shares in COCP as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 24.3% of COCP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.